Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jhe‐Cyuan, Hsu, Chia‐Lang, Hsieh, Min‐Shu, Lin, Chia‐Chi, Huang, Ta‐Chen, Kuo, Hung‐Yang, Shao, Yu‐Yun, Hsu, Chih‐Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396778/
https://www.ncbi.nlm.nih.gov/pubmed/37340770
http://dx.doi.org/10.1111/1759-7714.14997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396778/
https://www.ncbi.nlm.nih.gov/pubmed/37340770
http://dx.doi.org/10.1111/1759-7714.14997

Ejemplares similares